' Akciju kurss '

Datums	Sight Sciences Akciju kurss
5.09.2024.	6,41 undefined
4.09.2024.	6,41 undefined
3.09.2024.	6,29 undefined
30.08.2024.	6,77 undefined
29.08.2024.	6,76 undefined
28.08.2024.	6,72 undefined
27.08.2024.	6,81 undefined
26.08.2024.	7,05 undefined
23.08.2024.	6,76 undefined
22.08.2024.	6,32 undefined
21.08.2024.	6,37 undefined
20.08.2024.	6,08 undefined
19.08.2024.	6,38 undefined
16.08.2024.	6,05 undefined
15.08.2024.	6,03 undefined
14.08.2024.	5,79 undefined
13.08.2024.	5,95 undefined
12.08.2024.	5,79 undefined
9.08.2024.	5,96 undefined
8.08.2024.	5,83 undefined

Datums	Sight Sciences Apgrozījums	Sight Sciences EBIT	Sight Sciences Peļņa
2026e	105,40 milj. undefined	-24,64 milj. undefined	-25,85 milj. undefined
2025e	93,57 milj. undefined	-41,61 milj. undefined	-37,38 milj. undefined
2024e	84,00 milj. undefined	-49,07 milj. undefined	-47,95 milj. undefined
2023	81,06 milj. undefined	-57,27 milj. undefined	-55,55 milj. undefined
2022	71,33 milj. undefined	-83,95 milj. undefined	-86,24 milj. undefined
2021	48,96 milj. undefined	-51,48 milj. undefined	-62,96 milj. undefined
2020	27,64 milj. undefined	-32,19 milj. undefined	-34,69 milj. undefined
2019	23,35 milj. undefined	-24,04 milj. undefined	-25,87 milj. undefined
2018	7,53 milj. undefined	-14,30 milj. undefined	-14,29 milj. undefined

	Apgrozījums	EBIT	Peļņa
2018	7,53 milj. USD	-14,30 milj. USD	-14,29 milj. USD
2019	23,35 milj. USD	-24,04 milj. USD	-25,87 milj. USD
2020	27,64 milj. USD	-32,19 milj. USD	-34,69 milj. USD
2021	48,96 milj. USD	-51,48 milj. USD	-62,96 milj. USD
2022	71,33 milj. USD	-83,95 milj. USD	-86,24 milj. USD
2023	81,06 milj. USD	-57,27 milj. USD	-55,55 milj. USD
2024e	84,00 milj. USD	-49,07 milj. USD	-47,95 milj. USD
2025e	93,57 milj. USD	-41,61 milj. USD	-37,38 milj. USD
2026e	105,40 milj. USD	-24,64 milj. USD	-25,85 milj. USD

2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
7,00	23,00	27,00	48,00	71,00	81,00	83,00	93,00	105,00
-	228,57	17,39	77,78	47,92	14,08	2,47	12,05	12,90
71,43	69,57	66,67	83,33	81,69	85,19	-	-	-
5,00	16,00	18,00	40,00	58,00	69,00	0	0	0
-14,00	-24,00	-32,00	-51,00	-83,00	-57,00	-49,00	-41,00	-24,00
-200,00	-104,35	-118,52	-106,25	-116,90	-70,37	-59,04	-44,09	-22,86
-14,00	-25,00	-34,00	-62,00	-86,00	-55,00	-47,00	-37,00	-25,00
-	78,57	36,00	82,35	38,71	-36,05	-14,55	-21,28	-32,43
45,06	45,06	45,06	26,73	47,85	48,63	0	0	0
-	-	-	-	-	-	-	-	-

2018	2019	2020	2021	2022	2023

4,20	21,20	61,50	260,70	185,00	138,13
1,80	4,10	5,40	8,70	15,10	14,29
0	0	0	0	0	0
0,50	2,20	2,60	3,50	6,10	7,85
0,60	0,40	1,20	4,20	3,40	2,60
7,10	27,90	70,70	277,10	209,60	162,87
0,90	2,60	1,80	2,90	3,20	3,10
0	0	0	0	0	0
0	0	0	0	0	0
0	0	0	0	0	0
0	0	0	0	0	0
100,00	200,00	400,00	200,00	200,00	682,00
1,00	2,80	2,20	3,10	3,40	3,78
8,10	30,70	72,90	280,20	213,00	166,65

34,20	64,30	117,30	0	0	0,05
0,50	0,70	1,20	385,10	399,30	414,96
-29,50	-55,30	-90,00	-153,00	-239,20	-294,79
0	0	0	0	0	0
0	0	0	0	0	0
5,20	9,70	28,50	232,10	160,10	120,21
1,90	2,30	2,20	3,40	2,70	1,73
1,00	5,00	7,20	10,20	15,10	8,30
0	0	0	0	0	0
0	0	0	0	0	0
0	0	0	0	0	2,22
2,90	7,30	9,40	13,60	17,80	12,25
0	12,90	32,00	32,70	33,30	31,71
0	0	0	0	0	0
0	1,00	3,10	1,90	1,90	2,48
0	13,90	35,10	34,60	35,20	34,18
2,90	21,20	44,50	48,20	53,00	46,44
8,10	30,90	73,00	280,30	213,10	166,65

2018	2019	2020	2021	2022	2023
-14,00	-25,00	-34,00	-62,00	-86,00	-55,00
0	0	0	0	0	0
0	0	0	0	0	0
0	0	0	-4,00	-5,00	-9,00
0	1,00	1,00	19,00	28,00	31,00
0	0	0	3,00	3,00	4,00
0	0	0	0	0	0
-14,00	-25,00	-32,00	-52,00	-75,00	-47,00
0	0	0	0	0	0
0	0	0	0	0	0
0	0	0	0	0	0
0	0	0	0	0	0
0	14,00	20,00	0	0	0
12,00	30,00	53,00	257,00	1,00	1,00
12,00	42,00	73,00	252,00	1,00	1,00
-	-2,00	-	-4,00	-	-
0	0	0	0	0	0
-2,00	16,00	40,00	199,00	-75,00	-46,00
-15,05	-25,67	-33,12	-53,35	-76,94	-47,98
0	0	0	0	0	0

Sight Sciences Brutomarža	Sight Sciences Peļņas marge	Sight Sciences EBIT marža	Sight Sciences Peļņas marge
2026e	85,34 %	-23,37 %	-24,53 %
2025e	85,34 %	-44,47 %	-39,95 %
2024e	85,34 %	-58,42 %	-57,09 %
2023	85,34 %	-70,66 %	-68,53 %
2022	82,67 %	-117,69 %	-120,90 %
2021	82,41 %	-105,15 %	-128,59 %
2020	66,68 %	-116,46 %	-125,51 %
2019	71,95 %	-102,96 %	-110,79 %
2018	68,92 %	-189,91 %	-189,77 %

	Brutomarža	EBIT marža	Peļņas marge
2018	68,92 %	-189,91 %	-189,77 %
2019	71,95 %	-102,96 %	-110,79 %
2020	66,68 %	-116,46 %	-125,51 %
2021	82,41 %	-105,15 %	-128,59 %
2022	82,67 %	-117,69 %	-120,90 %
2023	85,34 %	-70,66 %	-68,53 %
2024e	85,34 %	-58,42 %	-57,09 %
2025e	85,34 %	-44,47 %	-39,95 %
2026e	85,34 %	-23,37 %	-24,53 %

Datums	Sight Sciences Apgrozījums uz vienu akciju	Sight Sciences EBIT uz vienu akciju	Sight Sciences Peļņa uz vienu akciju
2026e	2,10 undefined	0 undefined	-0,51 undefined
2025e	1,86 undefined	0 undefined	-0,74 undefined
2024e	1,67 undefined	0 undefined	-0,95 undefined
2023	1,67 undefined	-1,18 undefined	-1,14 undefined
2022	1,49 undefined	-1,75 undefined	-1,80 undefined
2021	1,83 undefined	-1,93 undefined	-2,36 undefined
2020	0,61 undefined	-0,71 undefined	-0,77 undefined
2019	0,52 undefined	-0,53 undefined	-0,57 undefined
2018	0,17 undefined	-0,32 undefined	-0,32 undefined

	Apgrozījums uz vienu akciju	EBIT uz vienu akciju	Peļņa uz vienu akciju
2018	0,17 USD	-0,32 USD	-0,32 USD
2019	0,52 USD	-0,53 USD	-0,57 USD
2020	0,61 USD	-0,71 USD	-0,77 USD
2021	1,83 USD	-1,93 USD	-2,36 USD
2022	1,49 USD	-1,75 USD	-1,80 USD
2023	1,67 USD	-1,18 USD	-1,14 USD
2024e	1,67 USD	0 USD	-0,95 USD
2025e	1,86 USD	0 USD	-0,74 USD
2026e	2,10 USD	0 USD	-0,51 USD

	Akciju skaits
2018	45,06 milj. Aktien
2019	45,06 milj. Aktien
2020	45,06 milj. Aktien
2021	26,73 milj. Aktien
2022	47,85 milj. Aktien
2023	48,63 milj. Aktien
2024e	48,63 milj. Aktien
2025e	48,63 milj. Aktien
2026e	48,63 milj. Aktien

Datums	EPS-prognoze	EPS-Faktiskais	Ziņojuma ceturksnis
30.06.2024.	-0,30	-0,25 (17,19 %)	2024 Q2
31.03.2024.	-0,28	-0,33 (-17,35 %)	2024 Q1
31.12.2023.	-0,32	-0,22 (31,95 %)	2023 Q4
30.09.2023.	-0,32	-0,27 (16,72 %)	2023 Q3
30.06.2023.	-0,35	-0,30 (13,87 %)	2023 Q2
31.03.2023.	-0,40	-0,35 (12,50 %)	2023 Q1
31.12.2022.	-0,43	-0,35 (17,71 %)	2022 Q4
30.09.2022.	-0,47	-0,46 (1,56 %)	2022 Q3
30.06.2022.	-0,43	-0,50 (-15,98 %)	2022 Q2
31.03.2022.	-0,41	-0,49 (-19,86 %)	2022 Q1
31.12.2021.	-0,40	-0,34 (14,85 %)	2021 Q4
30.09.2021.	-0,38	-0,43 (-14,67 %)	2021 Q3
30.06.2021.	-1,76	-1,83 (-4,01 %)	2021 Q2

%	Nosaukums	Akcijas	Izmaiņas	Datums
9,24 %	KCK, Ltd.	4 646 866	0	31.12.2023.
7,99 %	Allegro Investment, Inc.	4 022 118	-632 456	30.11.2023.
6,31 %	BofA Global Research (US)	3 174 134	3 094 315	31.12.2023.
5,76 %	UBS Financial Services, Inc.	2 895 958	2 881 750	31.12.2023.
4,34 %	Encrantz (Staffan)	2 181 314	1 602 478	30.11.2023.
3,45 %	Badawi (David)	1 735 468	-3128	3.04.2024.
3,24 %	Jackson Square Partners, LLC	1 629 746	174 737	31.12.2023.
2,93 %	The Vanguard Group, Inc.	1 474 682	72 778	31.12.2023.
2,72 %	BlackRock Institutional Trust Company, N.A.	1 368 652	-42 958	31.12.2023.
2,02 %	JP Morgan Asset Management	1 015 380	50 751	31.12.2023.
11,19 %	Badawi (Paul)	5 631 205	-12 571	3.04.2024.
1,49 %	Link (Matthew W)	747 572	747 572	14.11.2023.
1,33 %	Apollo Capital Management, L.P.	671 520	0	31.12.2023.
1,12 %	Geode Capital Management, L.L.C.	565 091	34 793	31.12.2023.
0,88 %	State Street Global Advisors (US)	441 644	-171 679	31.12.2023.
0,80 %	D. E. Shaw & Co., L.P.	404 835	142 142	31.12.2023.
0,60 %	Jacobs Levy Equity Management, Inc.	300 508	300 508	31.12.2023.
0,46 %	Park Sam Boong	229 640	-3414	3.04.2024.
0,39 %	Hayden (Jeremy Bragg)	197 119	-4893	3.04.2024.
0,39 %	Charles Schwab Investment Management, Inc.	196 956	-29 478	31.12.2023.
0,38 %	Point72 Asset Management, L.P.	193 001	27 923	31.12.2023.
0,38 %	Selnick (Jesse)	190 209	25 209	4.01.2023.
0,37 %	Northern Trust Investments, Inc.	184 583	-6620	31.12.2023.
0,35 %	Hicks (Mack H)	175 986	89 780	31.12.2022.
0,35 %	Palo Alto Investors LP	173 790	173 790	31.12.2023.
0,33 %	RTW Investments L.P.	164 806	164 806	31.12.2023.
0,29 %	Squarepoint Capital LLP	144 663	24 575	31.12.2023.
0,25 %	BMO Capital Markets (US)	123 500	123 500	31.12.2023.
0,24 %	Bridgeway Capital Management, LLC	121 400	121 400	31.12.2023.
0,20 %	JPMorgan Private Bank (United States)	102 253	18 139	31.12.2023.
0,17 %	Susquehanna International Group, LLP	85 903	85 903	31.12.2023.
0,17 %	Dimensional Fund Advisors, L.P.	83 866	-12 945	31.12.2023.
0,16 %	Acadian Asset Management LLC	78 415	78 415	31.12.2023.
0,15 %	Renaissance Technologies LLC	77 400	11 400	31.12.2023.
0,15 %	Morgan Stanley Smith Barney LLC	75 831	28 648	31.12.2023.
0,14 %	Jane Street Capital, L.L.C.	70 536	70 536	31.12.2023.
0,13 %	Morgan Stanley & Co. LLC	63 885	35 895	31.12.2023.
0,12 %	PanAgora Asset Management Inc.	59 190	39 333	31.12.2023.
0,12 %	BNY Mellon Asset Management	58 493	-42 582	31.12.2023.
0,11 %	Parametric Portfolio Associates LLC	57 039	-27 343	31.12.2023.
0,11 %	BlackRock Investment Management, LLC	56 651	-469	31.12.2023.
0,10 %	Millennium Management LLC	49 719	-139 552	31.12.2023.
0,09 %	Marshall Wace LLP	47 513	47 513	31.12.2023.
0,09 %	BlackRock Financial Management, Inc.	45 693	-21 204	31.12.2023.
0,08 %	Concurrent Investment Advisors, LLC	42 252	42 252	31.12.2023.
0,08 %	State Teachers Retirement System of Ohio	41 100	0	31.12.2023.
0,07 %	Voya Investment Management LLC	36 001	36 001	31.12.2023.
0,06 %	Larsen-Becker (Brenda Jane)	30 722	15 094	8.06.2023.
0,06 %	IBK Asset Management Co., Ltd.	30 288	-2148	30.09.2023.
0,06 %	Mazzacco (Catherine)	30 189	30 189	8.06.2023.
0,06 %	Barclays Bank PLC	29 725	20 081	31.12.2023.
0,06 %	Rhumbline Advisers Ltd. Partnership	27 822	0	31.12.2023.
0,05 %	Zurbay (Donald J)	27 034	27 034	8.06.2023.
0,05 %	Rogers (Erica J.)	27 034	27 034	8.06.2023.
0,05 %	American Century Investment Management, Inc.	24 934	9026	31.12.2023.
0,05 %	Avantis Investors	23 855	2487	31.03.2024.
0,04 %	Balyasny Asset Management LP	22 639	22 639	31.12.2023.
0,04 %	Rodberg (James)	21 299	20 600	16.03.2023.
0,04 %	AllianceBernstein L.P.	20 450	0	31.12.2023.
0,03 %	Mirae Asset Global Investments (USA) LLC	17 547	-8787	31.12.2023.
0,03 %	Fountain (Tamara R.)	15 094	15 094	8.06.2023.
0,03 %	State Street Global Advisors Ireland Limited	14 459	-53	30.04.2023.
0,03 %	XTX Markets LLC	14 115	14 115	31.12.2023.
0,03 %	Wolverine Trading, LLC	14 019	14 019	31.12.2023.
0,03 %	Northern Trust Global Investments	13 756	-3595	31.12.2023.
0,02 %	Tower Research Capital LLC	12 076	7764	31.12.2023.
0,02 %	Sygnia Asset Management	11 974	11 974	30.09.2023.
0,02 %	Schroeder (Valeska)	11 940	11 940	8.06.2023.
0,02 %	AQR Capital Management, LLC	10 950	10 950	31.12.2023.
0,02 %	SunAmerica Asset Management, LLC	10 742	-43	31.12.2023.
0,02 %	Prelude Capital Management, LLC	10 355	-6200	31.12.2023.
0,02 %	Lazard Asset Management, L.L.C.	9782	9782	31.12.2023.
0,02 %	Dimensional Fund Advisors, Ltd.	9425	0	31.01.2024.
0,02 %	DWS Investments UK Limited	9271	9271	31.03.2024.
0,02 %	Signaturefd, LLC	8433	0	31.12.2023.
0,02 %	RBC Capital Markets Wealth Management	8129	-7021	31.12.2023.
0,01 %	Fidelity Management & Research Company LLC	7439	3876	31.12.2023.
0,01 %	Mellon Investments Corporation	6505	-2	31.12.2023.
0,01 %	Becker (Brenda)	5974	-11 949	11.04.2023.
0,01 %	Legal & General Investment Management Ltd.	5754	-10 031	31.12.2023.
0,01 %	Wells Fargo Bank, N.A.	5670	1279	31.12.2023.
0,01 %	UBS Asset Management (Americas), Inc.	5600	5600	31.12.2023.
0,01 %	CIBC Asset Management Inc.	5300	0	31.12.2023.
0,01 %	Champlain Investment Partners, LLC	5200	5200	31.12.2023.
0,01 %	U.S. Bancorp Asset Management, Inc.	5200	5200	31.12.2023.
0,01 %	RBC Wealth Management, International	4610	1904	31.12.2023.
0,01 %	Manulife Investment Management (North America) Limited	4291	0	31.01.2024.
0,01 %	Mine & Arao Wealth Creation & Management, LLC	4068	0	31.12.2023.
0,01 %	ProShare Advisors LLC	3883	716	31.03.2024.
0,01 %	Simplex Trading, LLC	3636	3636	31.12.2023.
0,01 %	California State Teachers Retirement System	3557	-29 026	31.12.2023.
0,01 %	Citi Investment Research (US)	3278	3137	31.12.2023.
0,01 %	Credit Suisse Asset Management (Schweiz) AG	3162	3162	30.09.2023.
0,01 %	Amalgamated Bank Institutional Asset Management & Custody	3086	-225	31.12.2023.
0,01 %	Principal Global Investors (Equity)	2717	0	29.02.2024.
0,00 %	Huntington Private Financial Group	2500	0	31.12.2023.
0,00 %	New York State Common Retirement Fund	2413	0	31.12.2023.
0,00 %	Mackenzie Financial Corporation	2389	-1214	31.12.2023.
0,00 %	DFA Australia Ltd.	2150	4	31.12.2023.
0,00 %	Caldwell Sutter Capital, Inc	2000	0	31.03.2024.

What values and corporate philosophy does Sight Sciences represent?

Sight Sciences Inc represents a commitment to innovation, patient care, and improved healthcare outcomes. With a focus on developing cutting-edge medical devices and therapies, the company aims to enhance the lives of individuals suffering from eye diseases by providing effective treatment options. Sight Sciences Inc places great importance on advancing medical technology to address unmet needs and improve the quality of ophthalmic care. Through a patient-centered approach and dedication to research and development, Sight Sciences Inc is dedicated to making a positive impact in the field of ophthalmology while prioritizing the well-being of patients.

In which countries and regions is Sight Sciences primarily present?

Sight Sciences Inc is primarily present in the United States.

What significant milestones has the company Sight Sciences achieved?

Sight Sciences Inc has achieved several significant milestones. Firstly, the company successfully developed and commercialized innovative medical devices focused on eye health, such as the OMNI Surgical System and TearCare System. These technologies offer effective and minimally invasive solutions for glaucoma and dry eye disease. Additionally, Sight Sciences Inc received various regulatory approvals, including FDA clearances, reinforcing the safety and efficacy of their products. The company has also established strategic partnerships and collaborations with renowned ophthalmologists and institutions worldwide, fostering advancements in eye care. These milestones indicate Sight Sciences Inc's commitment to revolutionizing the field of ophthalmology and improving patients' quality of life.

What is the history and background of the company Sight Sciences?

Sight Sciences Inc. is a renowned company specializing in the development of innovative medical devices and technologies. Established in [insert year], Sight Sciences has been at the forefront of transforming ophthalmic care. With its visionary approach, the company aims to revolutionize the treatment of ocular conditions, particularly glaucoma and dry eye disease. Sight Sciences Inc. is committed to providing state-of-the-art solutions to enhance patient outcomes and improve quality of life. Having gained significant recognition in the medical industry, Sight Sciences continues to lead the way in delivering groundbreaking advancements that address the unmet needs of patients worldwide.

Who are the main competitors of Sight Sciences in the market?

The main competitors of Sight Sciences Inc in the market include companies such as Glaukos Corporation, Ivantis Inc, and Allergan Plc.

In which industries is Sight Sciences primarily active?

Sight Sciences Inc is primarily active in the medical technology industry.

What is the business model of Sight Sciences?

The business model of Sight Sciences Inc revolves around developing and commercializing innovative and minimally invasive medical devices for eye care professionals. The company aims to address unmet needs in the field of ophthalmology by providing advanced technologies that enhance patient outcomes. Sight Sciences Inc focuses on two primary areas: glaucoma and dry eye disease. By offering cutting-edge technologies like the OMNI Surgical System and TearCare, the company enables eye care professionals to diagnose, treat, and manage these conditions effectively. Sight Sciences Inc's business model is driven by its commitment to improving patient lives through the development of advanced medical devices for ophthalmic use.

Kāds ir Sight Sciences 2024 KGV?

Sight Sciences KGV ir -6,50.

Kāds ir Sight Sciences 2024 KUV?

Sight Sciences KUV ir 3,71.

Kāds AlleAktien kvalitātes vērtējums ir Sight Sciences?

AlleAktien kvalitātes vērtējums Sight Sciences ir 3/10.

Cik liels ir Sight Sciences 2024 apgrozījums?

gaidāmā Sight Sciences apgrozījums ir 84,00 milj. USD.

Cik liels ir Sight Sciences 2024 peļņa?

gaidāmā Sight Sciences peļņa ir -47,95 milj. USD.

Kas ir Sight Sciences?

Sight Sciences Inc is an innovative medical technology company specializing in the development of advanced medical devices for the treatment of eye diseases. The company was founded in 2011 and is headquartered in Menlo Park, California. Sight Sciences has developed a wide range of products tailored to the needs of ophthalmologists, optometrists, and patients. Their portfolio includes three main products: OMNI Surgical System, TearCare, and TRAB 360. OMNI Surgical System is a unique medical device used to treat various eye diseases. The system effectively lowers intraocular pressure by expanding the eye's natural drainage pathways. OMNI is a versatile system that can be used for different procedures such as canaloplasty or trabeculotomy. TearCare is another product from Sight Sciences used to treat dryness and other tear disorders. The device is easy to use and provides effective operation and quick results. It uses heat to open the glands in the eyelids and stimulate tear production. The third main product from Sight Sciences is TRAB 360, a device specifically designed for the treatment of glaucoma. The device can be used in combination with a surgical procedure to lower intraocular pressure and slow down the progression of the disease. Sight Sciences is committed to improving eye health worldwide. The company has focused on developing devices that can be easily and effectively used by physicians. Additionally, there is a focus on developing devices that are able to improve the quality of life for patients. Sight Sciences' business model is based on selling medical products to ophthalmologists and optometrists. As a company, Sight Sciences strives to develop new and innovative solutions for the treatment of eye diseases. The company keeps customer needs in mind and works closely with leading ophthalmologists to develop products that meet patient needs. Overall, Sight Sciences Inc has built a successful business model. The company has proven its ability to develop innovative products that provide real value to ophthalmologists and patients. With a diverse product portfolio and advanced technologies, Sight Sciences will continue to play an important role in the medical technology industry.

Cik liela ir Sight Sciences dividende?

Sight Sciences izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Cik bieži Sight Sciences maksā dividendes?

Dividendes pašlaik nevar aprēķināt Sight Sciences vai uzņēmums nedod dividendes.

Kas ir Sight Sciences ISIN?

Sight Sciences ISIN ir US82657M1053.

Kas ir Sight Sciences biržas kods?

Sight Sciences simbols ir SGHT.

Cik lielu dividendēm maksā Sight Sciences?

Pēdējo 12 mēnešu laikā Sight Sciences maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Sight Sciences plāno maksāt dividendes 0 USD apmērā.

Cik augsta ir Sight Sciences dividendu rentabilitāte?

Sight Sciences pašreizējā dividendu rentabilitāte ir .

Kad Sight Sciences maksā dividendes?

Sight Sciences maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Cik droša ir Sight Sciences dividende?

Sight Sciences pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Cik liela ir Sight Sciences dividende?

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Kurā sektorā atrodas Sight Sciences?

Sight Sciences tiek piešķirts nozarei "Veselība".

Wann musste ich die Aktien von Sight Sciences kaufen, um die vorherige Dividende zu erhalten?

Lai saņemtu pēdējo dividendu Sight Sciences apmērā 0 USD, kas tika izmaksāta 6.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 6.09.2024..

Kad Sight Sciences izmaksāja pēdējo dividendē?

Pēdējās dividendes izmaksa notika 6.09.2024..

Cik liela bija Sight Sciences dividende gadā 2023?

Gadā 2023, Sight Sciences izmaksāja 0 USD dividendes.

Kādā valūtā Sight Sciences izmaksā dividendes?

Sight Sciences dividendes tiek izmaksātas USD.

Tiešās emisijas	—
Nepārtrauktas emisijas no iegādātās enerģijas	—
Nepārtrauktas emisijas vērtību ķēdē	—
CO₂ emisijas	—
CO₂ samazināšanas stratēģija	✅
Oglekļa enerģija	❌
Atomenerģija	❌
Dzīvnieku izmēģinājumi	❌
Pelz & Leder	—
Pesticīdi	—
Palmas eļļa	—
Tabaka	❌
Ģenētiskā inženierija	❌
Klimata koncepcija	—
Ilgspējīga mežsaimniecība	—
Atkritumu pārstrādes noteikumi	❌
Videi draudzīga iepakojuma	❌
Bīstamās vielas	❌
Degvielas patēriņš un efektivitāte	❌
Ūdens patēriņš un efektivitāte	❌

Sieviešu īpatsvars darbinieku vidū	—
Sieviešu īpatsvars vadībā	—
Āzijas darbinieku īpatsvars	—
Āzijas vadības daļa	—
Hispano/latīņamerikāņu darbinieku īpatsvars	—
Hispano/latīņu pārstāvniecība vadībā	—
Akciju procentuālais daudzums melnādaino darbinieku vidū	—
Daļa melnādaino vadītāju	—
Baltie darbinieku īpatsvars	—
Baltie pārvaldības procenti	—
Pieaugušo satura	❌
Alkohols	❌
Aizsardzība	—
Ieroči	❌
Azartspēles	❌
Militārie līgumi	❌
Cilvēktiesību koncepcija	❌
Datumaizsardzības koncepcija	—
Darba aizsardzība un veselības aizsargāšana	✅
Katolisks	✅

Ilgtermiņa attīstības ziņojums	❌
Akciju turētāju iesaiste	❌
Atsaukšanas politika	❌
Kartel tiesības	❌

Sight Sciences Akciju biržas simbols	Sight Sciences FIGI
SGHT:US	BBG006BZHZC7
SGHT:UA	BBG011KQ69S0
SGHT:UC	BBG011KQ69T9
SGHT:UN	BBG011KQ69W5
SGHT:UP	BBG011KQ69X4
SGHT:UB	BBG011KQ69Z2
SGHT:UM	BBG011KQ6B14
SGHT:UX	BBG011KQ6B23
SGHT:UD	BBG011KQ6B78
SGHT:UW	BBG011KQ6B96
SGHT:UF	BBG011KQ6BB3
SGHT:VY	BBG011KQ6BC2
SGHT:VJ	BBG011KQ6BD1
SGHT:VK	BBG011KQ6BF9
SGHT:VF	BBG011KQ6BG8

Veic labākos ieguldījumus savā dzīvē fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Kurss

Akciju cena

SimbolsSGHT

ISINUS82657M1053

Sight Sciences akciju kurss

Kurs

Pārskats

Intraday funkcija

Kopējais atdevē un relatīvās cenas izmaiņas

Interpretācija un ieguldījumi

Sight Sciences Akciju vēsture

Sight Sciences Akcijas apgrozījums, EBIT, peļņa US82657M1053 ·

Apgrozījums, peļņa & EBIT

Apgrozījuma, EBIT un ienākumu izpratne

Gada analīze un salīdzinājumi

Ieguvumu izmantošana investīcijām

Ieguldījumu ieskati

Sight Sciences Apjoma, peļņas un EBIT vēsture

Sight Sciences Akciju Rādītāji

Peļņas un zaudējumu pārskats

Apjomi un izaugsme

Bruto marža

EBIT un EBIT marža

Ienākumi un izaugsme

Izlaistās akcijas

Gadskārtējās salīdzinājuma interpretācija

Gaidījumi un prognozes

Bilance

Bilances izpratne

Aktīvi

Parādsaistības

Pašu kapitāls

Gadu pēc gada analīze

Datu interpretācija

Sight Sciences akcijas maržas US82657M1053 ·

Maržas

Brutomaržas izpratne

EBIT maržas analīze

Apjoma maržas ieskati

Gaidāmo vērtību interpretēšana

Salīdzinošā analīze

Sight Sciences Maržas vēsture

Sight Sciences akciju apgrozījums, EBIT, peļņa uz vienu akciju US82657M1053 ·

Apjoms, EBIT un Peļņa uz vienu akciju

Apjoms uz vienu akciju

EBIT uz vienu akciju

Ienākumi uz vienu akciju

Gaidāmās vērtības

Sight Sciences Apjoma, peļņas un EBIT vēsture uz vienu akciju

Sight Sciences akcija un akciju analīze

Sight Sciences vērtējums pēc Fair Value

Fair Value

Fair Value izpratne

Ienākumu bāzes Fair Value

Apgrozījuma bāzes Fair Value

Dividende bāzes Fair Value

Gaidas un prognozes

Salīdzinošā analīze

Sight Sciences vērtējums pēc vēsturiskā PE, EBIT un P/S

Sight Sciences akciju skaits US82657M1053 ·

Apjoms, EBIT un Peļņa uz vienu akciju

Apjoms uz vienu akciju

EBIT uz vienu akciju

Ienākumi uz vienu akciju

Gaidāmās vērtības

Sight Sciences Peļņas prognozes

Sight Sciences Pelnīguma Pārsteigumi

Eulerpool ESG reitings Sight Sciences akcijai

Eulerpool World ESG Rating (EESG©)

45/ 100

🌱 Environment

👫 Social

🏛️ Governance

Vide (Environment)

Sociālais

Uzņēmuma vadība (Governance)

Sight Sciences Akciju akcionāru struktūra

Sight Sciences Valde un uzraudzības padome

Bieži uzdotie jautājumi par Sight Sciences akciju

Veic labākos ieguldījumus savā dzīvē
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Simbols
SGHT

ISIN
US82657M1053